Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Miscellaneous drugs with nephrotoxic potential (Sulfonamides, sulfadiazine, trimethoprim-sulfamethoxazole, pentamidine, pyrimethamine, dapsone, quinolones)

  • Chapter
Clinical Nephrotoxins

Abstract

A number of drugs of miscellaneous class are capable of producing various degrees of renal damage and will be reviewed in this Chapter. Some have been used extensively in the past for the treatment of general infections (sulfonamides), others have had specific indications (pentamidine, dapsone), and others such as quinolones are of more recent application. Many of these, however, have become currently important because of their use in the various complications occurring in patients with acquired immunodeficiency syndrome (AIDS). Table 1 lists drugs commonly used in patients with AIDS that are known to be nephrotoxic, whereas Table 2 lists those that are known not to be toxic to the kidneys.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Dowling HF, Lepper MH. Toxic reactions following therapy with sulfapyridine, sulfathiazole and sulfadiazine. JAMA 1943; 121: 1190–4.

    CAS  Google Scholar 

  2. Vilter CF, Blankehorn MA. Toxic reactions of the newer sulfonamides. JAMA 1944; 126: 691–5.

    CAS  Google Scholar 

  3. Lehr D. Clinical toxicity of sulfonamides. Ann NY Acad Sci 1957; 69: 417–47.

    PubMed  CAS  Google Scholar 

  4. Weinstein L, Madoff MA, Samet CM. The sulfonamides. N Engl J Med 1960; 263: 793–800 and 952–7.

    PubMed  CAS  Google Scholar 

  5. Dorfman LE, Smith JP. Sulfonamide crystalluria: a forgotten disease. J Urol 1970; 104: 482–3.

    PubMed  CAS  Google Scholar 

  6. Appel GB, Kunis CL. Acute interstitial nephritis. In: Cotran RS, Brenner BM, Stein JH, editors. Tubulointerstitial nephropathies. New York: Churchill, 1983: 151–185.

    Google Scholar 

  7. Simon DI, Brosius III FC, Rothstein DM. Sulfadiazine crystalluria revisited. The treatment of toxoplasma encephalitis in patients with acquired immunodeficiency syndrome. Arch Intern Med 1990; 150: 2379–84.

    PubMed  CAS  Google Scholar 

  8. Nissen NI, Aagaard K, Flindt-Hansen E. Sulfonamide hematuria frequency of injury to the urinary tract as estimated on the basis of 6084 cases treated with different sulfonamide-preparations. Acta Med Scand 1950; 138: 301–14.

    PubMed  CAS  Google Scholar 

  9. Finland M, Strauss E, Petersen OL. Sulfadiazine: therapeutic evaluation and toxic effect in four hundred and forty-six patients. JAMA 1941; 16: 2641–47.

    Google Scholar 

  10. Fox CL Jr, Jensen OJ Jr, Mudge GH. The prevention of renal obstruction during sulfadiazine therapy. JAMA 1943; 121: 1147–50.

    Google Scholar 

  11. Yap HK, Yip WCL, Tay SH, Lee BW. Reversible ultrasound findings in the kidneys of a patient with sulfonamide induced obstructive uropathy. J Singapore Pediatr Soc 1984; 26: 105–6.

    CAS  Google Scholar 

  12. Goadsby PJ, Donaghy AJ, Lloyd AR, Wakefield D. Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure. Ann Intern Med 1987; 107: 783–4.

    PubMed  CAS  Google Scholar 

  13. Sahai J, Heimberger T, Collins K, Kaplowitz L, Polk R. Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder. Am J Med 1988; 84: 791–2.

    PubMed  CAS  Google Scholar 

  14. Ventura MG, Wybram J, Farber CM. Sulfadiazine revisited. J Inf Dis 1989; 160: 556–7.

    CAS  Google Scholar 

  15. Carbone LG, Bendixen B, Appel GB. Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome. Am J Kidney Dis 1988; 12: 72–5.

    PubMed  CAS  Google Scholar 

  16. Christen S, Baumelou A, Bahri S, Ben Hmida M, Deray G, Jacobs C. Acute renal failure due to sulfadiazine in patients with AIDS. Nephron 1990; 55: 233–4.

    Google Scholar 

  17. Antopol W, Robinson H. Urolithiasis and renal pathology after oral administration of 2-sulfanilylamino (sulfapyridine). Proc Soc Exp Biol Med 1939; 40: 428–30.

    CAS  Google Scholar 

  18. Molina J-M, Belenfant X, Doco-Lecompte T, Idatte J-M, Modai J. Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis. AIDS 1991; 5: 587–9.

    PubMed  CAS  Google Scholar 

  19. Filks IN, Follador CR, Barbas Filho JV, Kairalla RA, Oliveira-Vianna Edos S, Stavale ML, de Carvalho CR. Kidney failure as a complication of the treatment of pulmonary paracoccidioidomycosis (in Portuguese). Rev Hosp Clin Fac Med Sao Paulo 1992; 47: 103–5.

    Google Scholar 

  20. Marques LP, Silva MT, Madeira EP, Santos OR. Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient. Nephron 1992; 62: 361.

    PubMed  CAS  Google Scholar 

  21. De Jaureguiberry JP, Reboul P, Vey N, Jaubert D. Acute renal failure caused by sulfadiazine crystalluria in AIDS. An historical resurgent iatrogenic complication (in French). Ann Med Interne (Paris) 1992; 143: 218–19.

    Google Scholar 

  22. Corbella X, Mascaró J, Santín M, Carratal J. Insuficiencia renal aguda por sulfadiazina en el tratamiento de una toxoplasmosis cerebral. Rev Clin Esp 1992; 190: 330–1.

    PubMed  CAS  Google Scholar 

  23. Farinas MC, Echevarria S, Sampedro I, Gonzalez A, Perez del Molino A, Gonzalez-Macias J. Renal failure due to sulphadiazine in AIDS patients with cerebral toxoplasmosis. J Intern Med 1993; 233: 365–7.

    PubMed  CAS  Google Scholar 

  24. Hein R, Brukhorst R, Thon WF, Schedel I, Schmidt RE. Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases. Clin Nephrol 1993; 39: 254–6.

    PubMed  CAS  Google Scholar 

  25. Haverkos HW. TE Study Group. Assessment of therapy for toxoplasma encephalitis. Am J Med 1987; 82: 907–14.

    PubMed  CAS  Google Scholar 

  26. Becker K, Jablonowski H, Häussinger D. Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome. Medicine (Balt.) 1996; 75: 185–94.

    CAS  Google Scholar 

  27. Kane D, Murphy JM, Keating S, Wilson GF, Mulcahy FM. Renal ultrasonic findings in sulfadiazine-induced renal failure. Br J Radiol 1996; 69; 925–8.

    PubMed  CAS  Google Scholar 

  28. Goodman LS, Gilman A. The pharmacological basis of therapeutics, 8th Ed, New York: McGraw Hill, 1991: 1047.

    Google Scholar 

  29. Bergan T, Brodwall EK, Vik-Mo H, Anstad U. Pharmacokinetics of sulphadizine, sulphamethoxazole and trimethoprim in patients with varying renal function. Infection 1979; 7 (suppl 4): S382–7.

    PubMed  CAS  Google Scholar 

  30. Berns JS, Cohen RM, Stumackher RJ, Rudnick MR. Renal aspects of therapy of human immunodeficiency virus and associated opportunistic infections. J Am Soc Nephrol 1991; 1: 1061–80.

    PubMed  CAS  Google Scholar 

  31. Swan SK, Bennett WM. Use of drugs in patients with renal failure. In: Schrier RW, Gottschalk CW, editors. Diseases of the Kidney 6th Ed., Little, Brown & Co., Boston, 1996; 2963–3017.

    Google Scholar 

  32. Portoles J, Torralbo A, Prats D, Blanco J, Barrientos A. Acute renal failure and sulfadiazine crystalluria in kidney transplant. Nephrol Dial transplant 1994; 9: 180–1.

    PubMed  CAS  Google Scholar 

  33. Oster S, Hutchison F, McCabe R. Resolution of acute renal failure in toxoplasmic encephalitis despite continuance of sulfadiazine. Rev Inf Dis 1990; 12: 618 – 20.

    CAS  Google Scholar 

  34. Robson M, Levi J, Dolber L, Rosenfeld JB. Acute tubulo-interstitial nephritis following sulfadiazine therapy. Isr J Med Sci 1970; 4: 561–6.

    Google Scholar 

  35. Nanra RS, Anderton JL, Evans M, Fairley KF, Kincaid-Smith P. The use of trimethoprim and sulfamethoxazole in the management of chronic and recurrent upper and lower urinary tract infection. Med J Aust 1971; 1: 25–6.

    PubMed  CAS  Google Scholar 

  36. Rosenfeld JB, Najenson T, Grosswater Z. Effect of long-term co-trimoxazole therapy on renal function. Med J Aust 1975; 2: 546–8.

    PubMed  CAS  Google Scholar 

  37. Bennet WM, Craven R. Urinary tract infections in patients with severe renal disease. Treatment with ampicillin and trimethoprim-sulfamethoxazole. JAMA 1976; 236: 946–8.

    Google Scholar 

  38. Lawson DH, Paice BJ. Adverse reactions to trimethoprim-sulfamethoxazole. Rev Inf Dis 1982; 4: 429–33.

    CAS  Google Scholar 

  39. Foltzer MA, Reese RE. Trimethoprim-sulfamethoxazole and other sulfonamides. Med Clin North Amer 1987; 71: 1177–94.

    CAS  Google Scholar 

  40. Bergan T, Brodwall EK. Kidney transport in man of Sulfamethoxazole and trimethoprim. Chemotherapy 1972; 17: 320–33.

    PubMed  CAS  Google Scholar 

  41. Trottier S, Bergeron MG, Lessard C. Intrarenal distribution of trimethoprim and sulfamethoxazole. Antimicrob Agents Chemother 1980; 17: 383–8.

    PubMed  CAS  Google Scholar 

  42. Tu Y-H, Allen LV Jr, Fiorica VM, Albers DD. Pharmacokinetics of trimethoprim in the rat. Am Pharmaceutical Sc 1989; 78: 556–60.

    CAS  Google Scholar 

  43. Cacini W, Myre SA. Uptake of trimethoprim by renal cortex. Biochem Pharmacol 1985; 34: 3483–8.

    PubMed  CAS  Google Scholar 

  44. Craig WA, Kunin CM. Distribution of trimethoprim-sulfamethoxazole in tissues of rhesus monkeys. J Infect Dis 1973; 128: S575–9.

    CAS  Google Scholar 

  45. Berglund F, Killander J, Pompeius R. Effect of trimethoprim-sulfamethoxazole on the renal excretion of creatinine in man. J Urol 1975; 114: 802–8.

    PubMed  CAS  Google Scholar 

  46. Shouval D, Ligumsky M, Ben-Ishary D. Effect of cotrimoxazole on normal creatinine clearance. Lancet 1978; 1: 244–5.

    PubMed  CAS  Google Scholar 

  47. Brautigam M, Forese P, Baethke R, Kessel M. Zur kreatininaus Scheidung beim Menschen nach Gabe von cotrimoxazole. Klin Wochenschr 1979; 57: 95–6.

    PubMed  CAS  Google Scholar 

  48. Trollfers B, Wahl M, Alestig K. Co-trimoxazole, Creatinine and renal function. J Infect 1980; 2: 221–6.

    Google Scholar 

  49. Kainer G, Rosenberg AR. Effect of co-trimoxazole on the glomerular filtration rate of healthy adults. Chemotherapy 1981; 27: 229–32.

    PubMed  CAS  Google Scholar 

  50. Lee J, Hollyer R, Rodelas R, Preuss HG. The influence of trimethoprim, sulfamethoxazole, and creatinine on renal organic anion and cation transport in rat kidney tissue. Tox Appl Pharmacol 1981; 58: 184–93.

    CAS  Google Scholar 

  51. Kalowski S, Nanra RS, Mathew TH, Kincaid-Smith P. Deterioration in renal function in association with cotrimoxazole therapy. Lancet 1973; 1: 394–7.

    PubMed  CAS  Google Scholar 

  52. Myre SA, McCann J, First MR, Cluxton RJ Jr. Effect of trimethoprim on serum creatinine in healthy and chronic renal failure volunteers. Ther Drug Monit 1987; 9: 161–5.

    PubMed  CAS  Google Scholar 

  53. Paap CM, Nahata MC. Clinical use of trimethoprim-sulfamethoxazole during renal dysfunction. Drug Intell Clin Pharm 1989; 23: 646–54.

    CAS  Google Scholar 

  54. Siber GR, Gorham CC, Ericson JF, Smith AL. Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole in children and adults with normal and impaired renal function. Rev Inf Dis 1982; 4: 566–78.

    CAS  Google Scholar 

  55. Eknoyan G. Acute renal failure associated with tubulointerstitial nephropathies. In: Brenner BM, Lazarus JM, editors. Acute renal failure, 2nd Ed, New York: Churchill Livingstone, 1988: 491–534.

    Google Scholar 

  56. Siegel WH. Unusual complications of therapy with sulfamethoxazole-trimethoprim. J Urol 1977; 117: 397.

    PubMed  CAS  Google Scholar 

  57. Nissenson AR, Wilson C, Holazo A. Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis. Am J Nephrol 1988; 7: 270–4.

    Google Scholar 

  58. Saltissi D, Pusey CD, Rainford DJ. Recurrent acute renal failure due to antibiotic-induced interstitial nephritis. Brit Med J 1979; 1: 1182–3.

    PubMed  CAS  Google Scholar 

  59. Jick H. Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients. Rev Infect Dis 1982; 4: 426–8.

    PubMed  CAS  Google Scholar 

  60. Hanley T. The synergy of trimethoprim and sulfonamides. Postgrad Med J 1969; 45 (suppl): 85.

    Google Scholar 

  61. Buchanan N. Sulfamethoxazole, hypoalbuminemia, crystalluria, and renal failure. Brit Med J 1978; 2: 172.

    PubMed  CAS  Google Scholar 

  62. Ahn YH, Goldman JM. Trimethoprim-sulfamethoxazole and hyponatremia. Ann Intern Med 1985; 103: 161–2.

    PubMed  CAS  Google Scholar 

  63. Wofsy CB. Use of trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Rev Infect Dis 1987; 92: S184–94.

    Google Scholar 

  64. Deans KW, Lang JR, Smith DE. Stability of trimethoprim-sulfamethoxazole injection in five infusion fluids. Am J Hosp Pharm 1982; 39: 1681–4.

    PubMed  CAS  Google Scholar 

  65. Richmond JM, Whitworth JA, Fairley KF, Kincaid-Smith P. Co-trimoxazole nephrotoxicity. Lancet 1979; 1: 493.

    PubMed  CAS  Google Scholar 

  66. Kraemer MJ, Kendall R, Hickman RO, Hass JE, Bierman CW. A generalized allergic reaction with acute interstitial nephritis following trimethoprim-sulfamethoxazole use. Ann Allergy 1982; 49: 323–5.

    PubMed  CAS  Google Scholar 

  67. Chandra M, Chandra P, McVicar M, Susin M, Teichberg S. Rapid onset of cotrimoxazole induced interstitial nephritis. Int J Pediatr Nephrol 1985; 8: 289–92.

    Google Scholar 

  68. Payne FE Jr, Giesecke TF. Multiple system reaction to trimethoprim-sulfamethoxazole. South Med J 1987; 80: 275–6.

    PubMed  Google Scholar 

  69. Dutertre JP, Despert F, Jonville AP, Autret E, Nivet H. Nécrose tubulaire aiguë au cours d’un traitement par Bactrim. Arch F Pediatr 1991; 48: 441–2.

    CAS  Google Scholar 

  70. Smith EJ, Light JA, Filo RS, Yum MN. Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients. JAMA 1980; 244: 360–1.

    PubMed  CAS  Google Scholar 

  71. Tasker PR, MacGregor GA, de Wardener HE. Use of co-trimoxazole in chronic renal failure. Lancet 1975; 1: 1216–8.

    PubMed  CAS  Google Scholar 

  72. Bourgault AM, Van Scoy RE, Brewer NS, Rosenow EC. Trimethoprim with sulfamethoxazole for treatment of infection with Pneumocystis carinii in renal insufficiency. Chest 1978; 74: 91–2.

    PubMed  CAS  Google Scholar 

  73. Brockener J, Boisen E. Fatal multisystem toxicity after co-trimoxazole. Lancet 1978; 1: 831.

    Google Scholar 

  74. Finalyson WB, Johnson G. Multisystem toxicity after co-trimoxazole. Lancet 1978; 2: 682.

    Google Scholar 

  75. Epstein M, Wright JM. Severe multisystem disease caused by trimethoprim-sulfamethoxazole: possible role of an in vitro lymphocyte assay. J Allergy Clin Immunol 1990; 86: 416–7.

    PubMed  CAS  Google Scholar 

  76. Thompson JF, Chalmers DH, Hunnisett AG, Wood RF, Morris PJ. Nephrotoxicity of trimethoprim- and cotrimoxazole in renal allograft recipients treated with cyclosporine. Transplantation 1983; 36: 204–6.

    PubMed  CAS  Google Scholar 

  77. Ringdén O, Myrenfors P, Klintmalm G, Tydén G, Ost L. Nephrotoxicity by cotrimoxazole and cyclosporin in transplant patients. Lancet 1984; 1: 1016–7.

    PubMed  Google Scholar 

  78. Berg KJ, Nordby G, Rootwelt K, Droseland O, Fauchald P, Mehl A, Narverud J, Talseth T. Effects on renal function of combined treatment with trimethoprim and cyclosporine A in kidney transplant patients. Transplant Proc 1988; 20: 413–5.

    PubMed  CAS  Google Scholar 

  79. Maki DG, Fox BC, Kuntz J, Sollinger HW, Beizer FO. A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation. Side-effects of trimethoprim-sulfamethoxazole, interaction with cyclosporin. J Lab Clin Med 1992; 119: 11–24.

    PubMed  CAS  Google Scholar 

  80. Kimmelt MS, Philips TM, Kramer NC, Thompson AM. In vitro and in vivo interaction of sulfamethoxazole with cyclosporine A measurement by high-pressure liquid chromatography (HRLC). Kidney Int 1985; 27: 343A.

    Google Scholar 

  81. Bourgoignie JJ. Renal complications of human immunodeficiency virus type 1. Kidney Int 1990; 37: 1571–84.

    PubMed  CAS  Google Scholar 

  82. Rao TK, Friedman EA. Renal syndromes in the acquired immunodeficiency syndrome (AIDS): lessons learned from analysis over 5 years. Artif Organs 1988; 12: 206–9.

    PubMed  CAS  Google Scholar 

  83. Humphreys MH, Schoenfeld PY. Renal complications in patients with the acquired immune deficiency syndrome (AIDS). Am J Nephrol 1987; 7: 1–7.

    PubMed  CAS  Google Scholar 

  84. Bourgoignie JJ, Ortiz-Butcher C, Green DF, Pardo V. Renal disease and AIDS. In: Broder S, Merigan TC Jr, Bolognesi D, editors. Textbook of AIDS disease. Williams and Wilkins, Baltimore, 1993; 597–608.

    Google Scholar 

  85. Walzer PD, Perl DP, Krogstad DJ, Rawson PG, Schultz MG. Pneumocystis carinii pneumonia in the United States. Epidemiologic, diagnostic, and clinical features. Ann Intern Med 1974; 80: 83–93.

    PubMed  CAS  Google Scholar 

  86. Glatt AE, Chirgwin K. Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients. Arch Intern Med 1990; 150: 271–9.

    PubMed  CAS  Google Scholar 

  87. Kovacs JA, Hiemenz JW, Macher AM, Stover D, Murray HW, Schelmhamer J, Lane HC, Urmacher C, Honig C, Longo DL, Parker MM, Natanson C, Parrillo JE, Fauci AS, Pizzo PA, Masur H. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984; 100: 663–71.

    PubMed  CAS  Google Scholar 

  88. Wofsy CB. Use of trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonitis in patients with acquired immunodeficiency with acquired immunodeficiency syndrome. Rev Infect Dis 1987; 9: S184–94.

    PubMed  Google Scholar 

  89. Wharton JM, Coleman DL, Wofsy CB, Luce JM, Blumenfeld W, Hadley WK, Ingram-Drake L, Volberd-ing PA, Hopewell PC. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired imunodeficiency syndrome. A prospective randomized trial. Ann Intern Med 1986; 105: 37–44.

    PubMed  CAS  Google Scholar 

  90. Sattler FR, Cowan R, Nielsen DM, Ruskin J. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study. Ann Intern Med 1988; 109: 280–7.

    PubMed  CAS  Google Scholar 

  91. Gordin FM, Simon GI, Wofsy CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1984; 100: 495–9.

    PubMed  CAS  Google Scholar 

  92. Zúñiga CA, Chua A, Alpert H, Vaamonde CA. Trimethoprim-sulfamethoxazole nephrotoxicity in patients with AIDS. Nat Kidney Found 1990; 20: A29.

    Google Scholar 

  93. Chua A, Züniga CA, Alpert H, Vaamonde CA. Trimethoprim-sulfamethoxazole nephrotoxicity in the sodium-depleted rat. J Am Soc Nephrol 1990; 1: 608.

    Google Scholar 

  94. Harvey AM, Malvin RL. Comparison of creatinine and inulin clearances in male and female rats. Am J Physiol 1965; 209: 849–52.

    PubMed  CAS  Google Scholar 

  95. Gouvea W, Vaamonde CM, Owens B, Alpert H, Pardo V, Vaamonde CA. The protection against gentamicin nephrotoxicity in the streptozotocin-induced diabetic rat is not related to gender. Life Sc 1992; 51: 1747–58.

    CAS  Google Scholar 

  96. Jick H, Derby LE. A large population-based follow-up study of trimethoprim-sulfamethoxazole, trimethoprim, and cephalexin for uncommon serious drugs toxicity. Pharmacotherapy 1995; 15: 428–32.

    PubMed  CAS  Google Scholar 

  97. Medina I, Mills J, Leoung G, Hopewell PC, Lee B, Modin G, Benowitz N, Wofsy CB. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990; 323: 776–82.

    PubMed  CAS  Google Scholar 

  98. Greenberg S, Reiser IW, Chou SY, Porush JG. Trimethoprim-sulfamethoxazole induces reversible hyperkalemia. Ann Intern Med 1993; 119: 291–5.

    PubMed  CAS  Google Scholar 

  99. Choi MJ, Fernández PC, Patnaik A, Coupage-Gerard B, D’Andrea D, Szerlip H, Kleyman TR. Brief report: trimethoprim-induced hyperkalemia in a patient with AIDS. N Engl J Med 1993; 328: 703–6.

    PubMed  CAS  Google Scholar 

  100. (a) Modest GA, Price B, Mascoli N; (b) Pennypacker LC, Mintzer J, Pitner J; (c) Canaday DH, Johnson JR; (d) Reiser IW, Chou S-Y; (e) Velazquez H, Ellison DH (letters). Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole. Ann Intern Med 1994; 120: 437–8.

    PubMed  CAS  Google Scholar 

  101. Funai N, Shimamoto Y, Matsuzaki M, Watanabe M, Tokioka T, Sueoka E, Suga K, Ono K, Sano M, Yamaguchi M. Hyperkalemia with renal tubular dysfunction by sulfamethoxazole-trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy. Haematologia 1993; 25: 137–41.

    PubMed  CAS  Google Scholar 

  102. Lawson DH, Jick H. Adverse reactions to co-trimoxazole in hospitalized medical patients. Am J Med Sci 1978; 275: 53–7.

    PubMed  CAS  Google Scholar 

  103. Kalin MF, Poretsky L, Seres DS, Zumoff B. Hyporeninemic hypoaldosteronism associated with acquired immune defiency syndrome. Am J Med 1987; 82: 1035–8.

    PubMed  CAS  Google Scholar 

  104. Guy R, Turberg Y, Davidson RN, Finnerty G, Mac-Gregor GA, Wise PH. Mineralocorticoid deficiency in HIV infection. Brit Med J 1989; 298: 1181.

    Google Scholar 

  105. Murphy CE, Ratnavel RG, Davidson AC. Mineralocorticoid deficient in HIV infection. Brit Med J 1989; 298: 1181.

    PubMed  CAS  Google Scholar 

  106. Velázquez H, Perazella MA, Wright FS, Ellison DH. Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med 1993; 119: 296–301.

    PubMed  Google Scholar 

  107. Schlanger LE, Kleyman TR, Ling BN. K+-sparing diuretic actions of trimethoprim: inhibition of Na+ channels in A6 distal nephron cells. Kidney Int 1994; 45: 1070–6.

    PubMed  CAS  Google Scholar 

  108. Murphy JL. Renal tubular acidosis in children treated with trimethoprim-sulfamethoxazole during therapy for acute lymphoid leukemia. Pediatrics 1992; 89: 1072–4.

    PubMed  CAS  Google Scholar 

  109. Schoenbach EB, Greenspan EM. The pharmacology, mode of action, and therapeutic potentialities of stilbamidine, pentamidine, propamidine, and other aromatic diamidines. A review. Medicine (Balt) 1948; 27: 327–77.

    CAS  Google Scholar 

  110. Van Hoof L, Henrard C, Peel E. Pentamidine in the prevention and treatment of trypanosomiasis. Trans Roy Soc Trop Med Hyg 1944; 37: 271–80.

    Google Scholar 

  111. Napier LE, Sen Gupta PC. The treatment of kala-azar with diaminodiphenoxypentane. Preliminary observations on the treatment of 32 cases. Indian Med Gaz 1943; 78: 177–83.

    Google Scholar 

  112. Ivady G, Paldy L, Koltay M, Toth G, Kovacs Z. Pneumocystis carinii pneumonia. Lancet 1967; 1: 616 – 7.

    PubMed  CAS  Google Scholar 

  113. Western KA, Perera DR, Schultz MG. Pentamidine isethionate in the treatment of Pneumocystis carinii pneumonia. Ann Intern Med 1970; 73: 695–702.

    PubMed  CAS  Google Scholar 

  114. Hughes WT, Feldman S, Chandhary SC, Ossi MJ, Cox F, Canyal SK. Comparison of pentamidine isethionate and trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia. J Pediatr 1978; 92: 285–291.

    PubMed  CAS  Google Scholar 

  115. Sands M, Kron MA, Brown RB. Pentamidine: a review. Rev Infect Dis 1985; 7: 625–34.

    PubMed  CAS  Google Scholar 

  116. Pearson RD, Hewlett EL. Pentamidine for the treatment of Pneumocystis carinii pneumonia and other protozoal diseases. Ann Intern Med 1985; 103: 782–6.

    PubMed  CAS  Google Scholar 

  117. Haley CJ. Pentamidine in Pneumocystis carinii pneumonia. Microlink Update 1987; 3: 1–4.

    Google Scholar 

  118. Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1984; 100: 495–9.

    PubMed  CAS  Google Scholar 

  119. Andersen R, Boedicker M, Ma M, Goldstein EJC. Adverse reactions associated with pentamidine isethionate in AIDS patients: recommendations for monitoring therapy. Drug Intell Clin Pharm 1986; 20: 862–8.

    PubMed  CAS  Google Scholar 

  120. Waskin H, Stehr-Green JK, Heimick CG, Sattler F. Risk factors for hypoglycemia associated with pentamidine therapy for Pneumocystis pneumonia. JAMA 1988; 260: 345–7.

    PubMed  CAS  Google Scholar 

  121. Lachaal M, Venuto RC. Nephrotoxicity and hyperkalemia in patients with AIDS treated with Pentamidine. Am J Med 1989; 87: 260–3.

    PubMed  CAS  Google Scholar 

  122. Chua A, Busse J, Alpert H, Vaamonde CA. Risk factors for pentamidine nephrotoxicity in AIDS patients. Nat Kidney Found 1989; 19: A5.

    Google Scholar 

  123. Briceland LL, Bailie GR. Pentamidine-associated nephrotoxicity and hyperkalemia in patients with AIDS. DICP, Ann Pharmacother 1991; 25: 1171–4.

    CAS  Google Scholar 

  124. Shuster M, Dunn M. Pentamidine and hematuria. Ann Intern Med 1986; 105: 106.

    Google Scholar 

  125. Sensaković JW, Suarez M, Perez G, Johnson ES, Smith LG. Pentamidine treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Association with acute renal failure and myoglobinuria. Arch Intern Med 1985; 145: 2247.

    Google Scholar 

  126. Chua A, Busse J, Papendick R, Alpert H, Vaamonde CA. Pentamidine nephrotoxicity in the rat. Kidney Int 1990; 37: 478A.

    Google Scholar 

  127. Stehr-Green J, Heimick CG. Pentamidine and renal toxicity. N Engl J Med 1985; 313: 694–5.

    PubMed  CAS  Google Scholar 

  128. Antoniskis D, Larsen RA. Acute, rapidly progressive renal failure with simultaneous use of amphotericin B and pentamidine. Antimicrob Agents Chemother 1990; 34: 470–2.

    PubMed  CAS  Google Scholar 

  129. Morin D, Dumas ML, Valette H, Dumas R. Insuffisance rénale aiguë et diabète-insulino-depéndant transitoires au décours du traitement d’un Kala-azar par pentamidine et antimoniate de N-méthylglucamine. Arch F Pediatr 1991; 48: 349–51.

    CAS  Google Scholar 

  130. Chunge CN, Gachihi G, Mulgai R, Wasunna K, Rashid JR, Chulay JD, Anabwani G, Oster CN, Bryceson AD. Visceral leishmaniasis unresponsive to antimonial drugs. II. Response to high dosage sodium stibogluconate or prolonged treatment with pentamidine. Trans R Soc Trop Med Hyg 1985; 79: 705–14.

    PubMed  Google Scholar 

  131. Golden JA, Chernoff D, Hollander H, Feigal D, Conte JE. Prevention of Pneumocystis carinii pneumonia by inhaled pentamidine. Lancet 1989; 1: 654–7.

    PubMed  CAS  Google Scholar 

  132. Nybo Jensen B, Nielsen TG, Lerche B, Jensen TH, Backer V, Mathiesen L, Nielsen JO, Skinhøj P. Prevention of Pneumocystis carinii pneumonia relapse by aerosolised pentamidine, 60 mg biweekly, using an Acorn System 22 nebuliser. Scand J Infect Dis 1990; 22: 533–6.

    Google Scholar 

  133. Link H, Vöhringer H-F, Wingen F, Brägas B, Schwardt A, Ehninger G. Pentamidine aerosol for prophylaxis of Pneumocystis carinii pneumonia after BMT. Bone Marrow Transplant 1993; 11: 403–6.

    PubMed  CAS  Google Scholar 

  134. Miller RF, Delany S, Semple SJG. Acute renal failure after nebulised pentamidine. Lancet 1989; 1: 1271–2.

    PubMed  CAS  Google Scholar 

  135. Chapelon C, Raguin G, De Gennes C. Renal insufficiency with nebulised pentamidine. Lancet 1989; 2: 1045–6.

    PubMed  CAS  Google Scholar 

  136. Soo Hoo GW, Mohsenifar Z, Meyer RD. Inhaled or intravenous pentamidine therapy for Pneumocystis carinii pneumonia in AIDS. A randomized trial. Ann Intern Med 1990; 113: 195–202.

    PubMed  CAS  Google Scholar 

  137. French MH, Milne AH. Some metabolic disturbances in domestic stock following injection of 4:4′-diamidine 1:5 diphenoxypentane. Vet Rec 1941; 53: 413–6.

    Google Scholar 

  138. Wien R, Freeman W, Scotcher NM. The metabolic effects produced by certain aromatic diamidines. Ann Trop Med Parasitol 1943; 37: 19–33.

    CAS  Google Scholar 

  139. Makula DR, Waalkes TP. Interaction between aromatic diamidines and nucleic acids: possible implications for chemotherapy. J Natl Cancer Inst 1975; 54: 305–9.

    Google Scholar 

  140. Feddersen A, Sack K. Experimental studies on the nephrotoxicity of pentamidine in rats. J Antimicrob Chemother 1991; 28: 437–46.

    PubMed  CAS  Google Scholar 

  141. Waalkes TP, Denham C, DeVita VT. Pentamidine: clinical pharmacologic correlations in man and mice. Clin Pharmacol Ther 1970; 11: 505–12.

    PubMed  CAS  Google Scholar 

  142. Bernard EM, Donnelly HJ, Maker MP, Armstrong D. Use of a new bioassay to study pentamidine pharmacokinetics. J Infect Dis 1985; 152: 750–4.

    PubMed  CAS  Google Scholar 

  143. Berger BJ, Hall JE, Tidwell RR. The distribution of multiple doses of pentamidine in rats. Pharmacol Toxicol 1990; 66: 234–6.

    PubMed  CAS  Google Scholar 

  144. Navim TR, Dickinson CM, Adams SR, Mayersohn M, Juranek DD. Effect of azotemia in dogs on the pharmacokinetics of pentamidine. J Infect Dis 1987; 155: 1020–6.

    Google Scholar 

  145. Berger BJ, Lombardy RJ, Marbury GD, Bell CA, Dykstra CC, Hall JE, Tidwell RR. metabolic N-hydro-xilation of pentamidine in vitro. Antimicrob Agents Chemother 1990; 34: 1678–84.

    PubMed  CAS  Google Scholar 

  146. Conte JE Jr, Upton RA, Phelps RT, Wofsy CB, Zurlinder E, Lin ET. Use of a specific and sensitive assay to determine pentamidine pharmacokinetics in patients with AIDS. J Infect Dis 1986; 154: 923–9.

    PubMed  Google Scholar 

  147. Conte JE Jr. Pharmacokinetics of intravenous pentamidine in patients with normal renal function or receiving hemodialysis. J Infect Dis 1991; 163: 169 – 75.

    PubMed  Google Scholar 

  148. Donnelly H, Bernard EM, Rothkotter H, Gold JWM, Armstrong D. Distribution of pentamidine in patients with AIDS. J Infect Dis 1988; 157: 985–9.

    PubMed  CAS  Google Scholar 

  149. Gambertoglio JG, Aweeka FT, Blythe WB. Use of drugs in patients with renal failure. In: Schrier RW, Gottschalk CW, editors. Diseases of the Kidney, 5th Ed. Boston: Little, Brown and Co, 1993: 3211–68.

    Google Scholar 

  150. Fortunato SJ, Bawdon RE. Determination of pentamidine transfer in the in vitro perfused human cotyledon with high-performance liquid chromatography. Am J Obstet Gynecol 1989; 160: 759–61.

    PubMed  CAS  Google Scholar 

  151. Bouchard PH, Sai P, Reach G, Caubarrere I, Ganeval D, Assan R. Diabetes mellitus following pentamidine-induced hypoglycemia in humans. Diabetes 1982; 31: 40–5.

    PubMed  CAS  Google Scholar 

  152. Sharpe SM. Pentamidine and hypoglycemia. Ann Intern Med 1983; 99: 128.

    PubMed  CAS  Google Scholar 

  153. Murdoch JK, Keystone JS. Pentamidine and hypoglycemia. Ann Intern Med 1983; 99: 879.

    Google Scholar 

  154. Stahl Bayliss CM, Kaiman CM, Laskin OL. Pentamidine induced hypoglycemia in patients with the acquired immune deficiency syndrome. Clin Pharmacol Ther 1986; 39: 271–5.

    PubMed  CAS  Google Scholar 

  155. Collins RJ, Pien FD, Houk JH. Case report: insulin-dependent diabetes mellitus associated with pentamidine. Am J Med Sci 1989; 296: 174–5.

    Google Scholar 

  156. DeVita VT, Emmer M, Levine A, Jacobs B, Berard C. Pneumocystis carinii pneumonia: successful diagnosis and treatment of two patients with associated malignant processes. N Engl J Med 1969; 280: 287–91.

    PubMed  CAS  Google Scholar 

  157. Petz S, Hashmi S. Pentamidine-induced severe hyperkalemia. Am J Med 1989; 87: 698–9.

    Google Scholar 

  158. Buff DD, Aboal AA. Pentamidine-associated renal dysfunction and hyperkalemia. Am J Med 1990; 88: 552.

    PubMed  CAS  Google Scholar 

  159. Bibler MR, Chou T, Toltzis RJH, Wade PA. Recurrent ventricular tachycardia due to pentamidine-induced cardio-toxicity. Chest 1988; 94: 1303–6.

    PubMed  CAS  Google Scholar 

  160. Balshev U, Berild D, Nielsen TL. Cardiac arrest during treatment of Pneumocystis carinii pneumonia with intravenous pentamidine isethionate. Scand J Infect Dis 1992; 24: 111–2.

    Google Scholar 

  161. Kleyman TR, Roberts C, Ling BN. A mechanism for pentamidine-induced hyperkalemia: Inhibition of distal nephron sodium transport. Ann Intern Med 1995; 122: 103–6.

    PubMed  CAS  Google Scholar 

  162. Shah GM, Alvarado P, Kirschenbaum MA. Symptomatic hypocalcemia and hypomagnesemia with renal magnesium wasting associated with pentamidine therapy in a patient with AIDS. Am J Med 1990; 89: 380–2.

    PubMed  CAS  Google Scholar 

  163. Burnett RJ, Reents SB. Severe Hypomagnesemia induced by pentamidine. Drug Intell Clin Pharm 1990; 24: 239–40.

    CAS  Google Scholar 

  164. Gradon JD, Fricchione L, Sepkowitz D. Severe Hypomagnesemia associated with pentamidine therapy. Rev Infect Dis 1991; 13: 511–21.

    PubMed  CAS  Google Scholar 

  165. Mani S. Pentamidine-induced renal magnesium wasting. AIDS 1992; 6: 594–5.

    PubMed  CAS  Google Scholar 

  166. Youle MS, Clarbour J, Gazzard B, Chanas A. Severe hypocalcemia in AIDS patients treated with foscarnet and pentamidine. Lancet 1988; 1: 1455–6.

    PubMed  CAS  Google Scholar 

  167. Hitchings GH. The use of an antimetabolite in chemotherapy of malaria and other infections. Clin Pharmacol Ther 1960; 1: 570–89.

    CAS  Google Scholar 

  168. Ritschel WA, Hammer GV, Thompson GA. Pharmacokinetics of antimalarials and proposals for dosage regimens. Int J Clin Pharmacol 1978; 16: 395–401.

    CAS  Google Scholar 

  169. White NJ. Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacol 1985; 10: 187–215.

    CAS  Google Scholar 

  170. Opravil M, Heald A, Lazzarin A, Hirschel B, Lüthy R, and the Swiss Group for Clinical Studies in AIDS. Combined prophylaxis of Pneumocystis carinii pneumonia and toxoplasmosis: dapsone + pyrimethamine vs aerolized pentamidine. AIDS 1992; 6: S8.

    Google Scholar 

  171. Opravil M, Keusch G, Lüthy R. Pyrimethamine inhibits renal secretion of creatinine. Antimicrob Agents Chemother 1993; 37: 1056–60.

    PubMed  CAS  Google Scholar 

  172. Lee BL, Medina I, Benowitz NL, Jacob P III, Wofsy CB, Mills JV. Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989; 110: 606–11.

    PubMed  CAS  Google Scholar 

  173. Belmont A. Dapsone-induced nephrotic syndrome. JAMA 1967; 200: 262–3.

    Google Scholar 

  174. Hoffbrand BI. Dapsone and renal papillary necrosis. Brit Med J 1978; 1: 78.

    PubMed  CAS  Google Scholar 

  175. Chugh KS, Singhal PC, Sharma BK, Mahakur AC, Pal Y, Datta BN, Das KC. Acute renal failure due to intravascular hemolysis in the North Indian patients. Am J Med Sc 1977; 274: 139–46.

    CAS  Google Scholar 

  176. Kenner DJ, Holt K, Agnello R, Chester GH. Permanent retinal damage following massive dapsone overdose. Brit J Ophtalmol 1980; 64: 741–4.

    CAS  Google Scholar 

  177. Hooper DC. Quinolones. In: Mandel GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases, 4th Ed., New York, Churchill, Livingstone, 1995; 364–76.

    Google Scholar 

  178. Lesher GY, Froelich EJ, Gruett MD. 1,8-naphthyridine derivatives, a new class of chemotherapeutic agents. J Med Pharmacol Chem 1962; 5: 1063.

    CAS  Google Scholar 

  179. USPDI. Fluoroquinolones (systemic). In: The United States Pharmacopeial Convention, Inc. Drug information for the health Care Professional. 17th Ed, Rockville, 1997: 1464–72.

    Google Scholar 

  180. Ferry N, Cuisinaud G, Pozet NV, Zech PY, Sassard J. Nalidixic acid kinetics after single and repeated oral doses. Clin Pharmacol Ther 1981; 29: 695–8.

    PubMed  CAS  Google Scholar 

  181. Portmann GA, McChesney EW, Stander H, Moore WE. Pharmacokinetic model for nalidixic acid in man. II. Parameters for absortion, metabolism, and elimination. J Pharm Sci 1966; 55: 72–8.

    PubMed  CAS  Google Scholar 

  182. Porter GA. Antimicrobial nephrotoxicity. In: Massry SG, Glassock RJ, editors. Textbook of nephrology, 2nd Ed. Baltimore: Williams & Wilkins, 1989: 812–8.

    Google Scholar 

  183. Bergan T. Pharmacokinetics of fluorinated quinolones. In: Andreoli VT, editor. The Quinolones. London: Academic Press, 1988: 119–54.

    Google Scholar 

  184. Gerding DN, Hitt JA. Tissue penetration of the new quinolones in humans. Rev Inf Dis 1989; 11: S1046–57.

    CAS  Google Scholar 

  185. Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC. Effect of renal function on bioavailability of ciprofloxacin. Antimicrob Agents Chemother 1990; 34: 1031–4.

    PubMed  CAS  Google Scholar 

  186. Drusano GL. An overview of the pharmacology of intravenously administered ciprofloxacin. Am J Med 1987; 82: S339–45.

    Google Scholar 

  187. Rohwedder R, Bergan T, Thorsteinsson SB, Scholl H. Transintestinal elimination of ciprofloxacin. Chemotherapy 1990; 36: 76–84.

    Google Scholar 

  188. Ljungberg B, Nilsson-Ehle I. Pharmacokinetics of ciprofloxacin in the elderly: increased oral bioavailability and reduced renal clearance. Eur J Clin Microbiol Infect Dis 1989; 8: 515–20.

    PubMed  CAS  Google Scholar 

  189. Stahlmann R, Lode H. Safety overview: toxicity, adverse effects, and drug interactions. In: Andreoli VT, editor. The quinolones. London: Academic Press, 1988: 201–33.

    Google Scholar 

  190. Johnson PRE, Liu Yin JA, Tooth JA. A randomized trial of high-dose ciprofloxacin versus azlocillin and netilmicin in the empirical therapy of febrile neutropenic patients. J Antimicrob Chemother 1992; 30: 203–14.

    PubMed  CAS  Google Scholar 

  191. Ball P. Ciprofloxacin: an overview of adverse experiences. Antimicrob Chemother 1986; 18: S187–93.

    Google Scholar 

  192. Arcieri G, Griffith E, Gruenwaldt G, Heyd A, O’Brien B, Becker N, August R. Ciprofloxacin: an update on clinical experience. Am J Med 1987; 82: S381–6.

    Google Scholar 

  193. Gerritsen WR, Peters A, Henry FC, Brouwes JRB Jr. Ciprofloxacin-induced nephrotoxicity. Nephrol Dial Transplant 1987; 2: 382–3.

    PubMed  CAS  Google Scholar 

  194. Rippelmeyer DJ, Synhavsky A. Ciprofloxacin and allergic interstitial nephritis. Ann Intern Med 1988; 109: 170.

    PubMed  CAS  Google Scholar 

  195. Lee CW, Fialkow RZ, VanWyck D. Letter. Am J Kidney Dis 1989; 8: 510–1.

    Google Scholar 

  196. Hootkins R, Fenves AZ, Stephens MK. Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature. Clin Nephrol 1989; 32: 75–8.

    PubMed  CAS  Google Scholar 

  197. Ying L, Johnson C. Ciprofloxacin-induced interstitial nephritis. Clin Pharm 1989; 8: 518–21.

    PubMed  CAS  Google Scholar 

  198. Helmink R, Bunediktsson H. Ciprofloxacin-induced allergic interstitial nephritis. Nephron 1990; 55: 432–3.

    PubMed  CAS  Google Scholar 

  199. Rastogi S, Atkinson J, McCarthy J. Allergic nephropathy associated with ciprofloxacin. Mayo Clin Proc 1990; 65: 987–9.

    PubMed  CAS  Google Scholar 

  200. Allon M, Lopez E, Min K-W Acute renal failure due to ciprofloxacin. Arch Intern Med 1990; 150: 2187–9.

    PubMed  CAS  Google Scholar 

  201. Murray K, Wilson M. Suspected ciprofloxacin-induced interstitial nephritis. DICP. Ann Pharmacother 1990; 24: 3790–800.

    Google Scholar 

  202. Hatton J, Haagensen D. Renal dysfunction associated with ciprofloxacin. Pharmacotherapy 1990; 10: 337–40.

    PubMed  CAS  Google Scholar 

  203. Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K. Typhoid fever, ciprofloxacin, and renal failure. Arch Dis Child 1991; 66: 1083–4.

    PubMed  CAS  Google Scholar 

  204. Arviewux C, Charasse C, Guilhem I, Rivalan J, Le Pogamp P, Raniee MP. Insuffisance rénale aiguë par néphropathie tubulo-interstitielle après treatement par Ciprofloxacine. Presse Méd 1991; 20: 1686.

    Google Scholar 

  205. Gonski PN. Ciprofloxacin-induced renal failure in an elderly patient. Med J Austral 1991; 154: 638–9.

    PubMed  CAS  Google Scholar 

  206. George MJ, Dew RB III, Daly JS. Acute renal failure after an overdose of ciprofloxacin. Arch Intern Med 1991; 151: 620.

    PubMed  CAS  Google Scholar 

  207. Andersen I, Sjostrom P. Ciprofloxacin can cause allergic interstitial nephritis with acute renal failure (Swedish). Lakartidningen 1991; 88: 1298–9.

    PubMed  CAS  Google Scholar 

  208. Bailey JR, Trott SA, Phibrick JT. Ciprofloxacin-induced acute interstitial nephritis. Am J Nephrol 1992; 12: 271–3.

    PubMed  CAS  Google Scholar 

  209. La WK, Rolston KVI, Rubenstein EB, Bodey GP. Ciprofloxacin-induced nephrotoxicity in patients with cancer. Arch Intern Med 1993; 153: 1258–62.

    Google Scholar 

  210. Lien Y-HH, Hansen R, Kern WF, Bangert J, Nagle RB, Ko M, Siskind MS. Ciprofloxacin-induced granulomatous interstitial nephritis and localized elastolysis. Am J Kidney Dis 1993; 22: 598–602.

    PubMed  CAS  Google Scholar 

  211. Schluter G. Ciprofloxacin: review of potential toxicologic effects. Am J Med 1987; 82: S91–3.

    Google Scholar 

  212. Christ W, Lehnert T, Ulbrich B. Specific toxicologic aspects of the quinolones. Rev Infect Dis 1988; 10: S141–6.

    PubMed  CAS  Google Scholar 

  213. Thorsteinsson SB, Bergan T, Oddsdottir S, Rowwedder R, Holin R. Crystalluria and ciprofloxacin: influence of urinary pH and hydration. Chemotherapy 1986; 32: 408–17.

    PubMed  CAS  Google Scholar 

  214. Kruger HV, Schuler U, Prokasch B, Gobel M, Ehninger G. Investigation of potential interaction of ciprofloxacin with cyclosporine in bone marrow transplant recipients. Antimicrob Agents Chemother 1990; 34: 1048–52.

    PubMed  CAS  Google Scholar 

  215. Robinson JA, Venezio FR, Costanzo-Nordin MR, Pifar-re R, O’Keefe PJ. Patients receiving quinolones and cyclosporine after heart transplantation. J Heart Transplant 1990; 9: 30–1.

    PubMed  CAS  Google Scholar 

  216. Avent CK, Krimsky D, Kirklin JK, Bourge RC, Fige WD. Synergistic nephrotoxicity due to cyprofloxacin and cyclosporine. Am J Med 1988; 83: 452–3.

    Google Scholar 

  217. Elston RA, Taylor J. Possible interaction of ciprofloxacin with cyclosporin A. J Antimicrob Chemother 1988; 21: 452–3.

    Google Scholar 

  218. Thompson DJ, Menkis AH, McKenzie FN. Norfloxacin-cyclosporine interaction. Transplantation 1988; 46: 312–3.

    Google Scholar 

  219. Vogt P, Schorn T, Frei U. Ofloxacin in the treatment of urinary tract infection in renal transplant recipient. Infection 1988; 16: 175–8.

    PubMed  CAS  Google Scholar 

  220. Gluckman E, Devergie A, Lokiec F, de Castro H, Meletis J, Traineau R, Cosset JM, Le Mercier N, Varrin F, Cavazzano M. Role of immunosuppressive drugs for prevention of graft-host disease after human HLA matched bone marrow transplantation. Transplant Proc 1987; 19: S61–5.

    Google Scholar 

  221. Rossi E, Silverstri MG, Manari A, Savazzi G, Migone L. Acute renal failure and piromidic acid. Nephron 1982; 32: 80–2.

    PubMed  CAS  Google Scholar 

  222. Godin M, Ducastelle T, Bercoff E, Dubois D, Fillatre JP, Boureille J. Renal failure and quinolone. Nephron 1984; 37: 70–2.

    PubMed  CAS  Google Scholar 

  223. Boelaert J, de Jaegere PP, Daneeis R, Schurgers M, Gordts B, van Landuyt HW. Case report of renal failure during norfloxacin therapy. Clin Nephrol 1986; 25: 272.

    PubMed  CAS  Google Scholar 

  224. Krasula RW, Pernet AG. Comparison of organ-specific toxicity of temafloxacin in animals and humans. Am J Med 1991; 91: S38–41.

    Google Scholar 

  225. Norbby SR. Assessment of adverse events during drug development: experience with temafloxacin. J Antimicrob Chemother 1991; 28: Sp 11–20.

    Google Scholar 

  226. Davis GJ, McKenzie BE. Toxicologic evaluation of ofloxacin. Am J Med 1989; 87: S43–6.

    Google Scholar 

  227. Mouton Y, Ajana F, Chidiac C, Capron MH, Home P, Masquelier A-M. A multicenter study of Iomefloxacin and trimethoprim-sulfamethoxazole in the treatment of uncomplicated acute pyelonephritis. Am J Med 1992; 92: S87–90.

    Google Scholar 

  228. Shiba K, Saito A, Shimada J, Hori S, Kaji M, Miyahara T, Kusajima H, Kaneko S, Saito S, Ooie T, Uchida H. Renal handling of fleroxacin in rabbits, dogs, and humans. Antimicrob Agents Chemother 1990; 34: 58–64.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Carlos A. Vaamonde
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Nephrology and Hypertension, University of Antwerp, Belgium

    M. E. De Broe  & G. A. Verpooten  & 

  2. Department of Medicine, The Oregon Health Sciences University, Portland, Oregon, 97201, USA

    G. A. Porter

  3. Division of Nephrology, The Oregon Health Sciences University, Portland, Oregon, 97201, USA

    W. M. Bennett

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Vaamonde, C.A. (1998). Miscellaneous drugs with nephrotoxic potential (Sulfonamides, sulfadiazine, trimethoprim-sulfamethoxazole, pentamidine, pyrimethamine, dapsone, quinolones). In: De Broe, M.E., Porter, G.A., Bennett, W.M., Verpooten, G.A. (eds) Clinical Nephrotoxins. Springer, Dordrecht. https://doi.org/10.1007/978-94-015-9088-4_10

Download citation

  • DOI: https://doi.org/10.1007/978-94-015-9088-4_10

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-015-9090-7

  • Online ISBN: 978-94-015-9088-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation